19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform,...
18:50 , Jul 11, 2018 |  BC Extra  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said Wednesday. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform, which...
19:10 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Visterra tops off series C round

On Oct. 5, anti-infectives company Visterra Inc. (Cambridge, Mass.) raised $23.6 million in an extension of a series C round, bringing the round's total to $46.7 million. Visterra raised an initial $23.1 million close in...
11:02 , Oct 5, 2017 |  BC Extra  |  Financial News

Visterra tops off series C round

Anti-infectives company Visterra Inc. (Cambridge, Mass.) raised $23.6 million in an extension of a series C round, bringing the round's total to $46.7 million. Visterra raised an initial $23.1 million close in June 2016. New investors...